Paclitaxel, Carboplatin, Olaparib, Niraparib, Imnn-001 (Il-12 Plasmid Formulated With Peg-Pei-Cholesterol Lipopolymer)
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Cancer
Phase III
Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Apr 01, 2025
―
Imnn-101
Sars Cov 2 Infection
Phase I/II
Completed
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
Feb 22, 2024
―
Bevacizumab, Paclitaxel, Carboplatin, Imnn-001
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Phase I/II
Recruiting
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Feb 13, 2023
―
Paclitaxel, Carboplatin, Imnn-001
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase I/II
Active Not Recruiting
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Jan 03, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Imunon (CBO0) have in its pipeline
CBO0 is currently developing the following drugs: Paclitaxel, Carboplatin, Olaparib, Niraparib, Imnn-001 (Il-12 Plasmid Formulated With Peg-Pei-Cholesterol Lipopolymer), Imnn-101, Bevacizumab, Paclitaxel, Carboplatin, Imnn-001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.